SYRE
Price
$85.69
Change
+$5.79 (+7.25%)
Updated
Oct 9 closing price
Capitalization
7.56B
25 days until earnings call
Intraday BUY SELL Signals
TRVI
Price
$13.19
Change
+$0.37 (+2.89%)
Updated
Oct 9 closing price
Capitalization
2.05B
31 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SYRE vs TRVI

SYRE vs TRVI Comparison Chart in %
View a ticker or compare two or three
VS
SYRE vs. TRVI commentary
Oct 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Hold and TRVI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
SYRE vs TRVI: Fundamental Ratings
SYRE
TRVI
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
10025
SMR RATING
1..100
9695
PRICE GROWTH RATING
1..100
3563
P/E GROWTH RATING
1..100
71100
SEASONALITY SCORE
1..100
28n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TRVI's Valuation (43) in the Pharmaceuticals Major industry is in the same range as SYRE (68). This means that TRVI’s stock grew similarly to SYRE’s over the last 12 months.

TRVI's Profit vs Risk Rating (25) in the Pharmaceuticals Major industry is significantly better than the same rating for SYRE (100). This means that TRVI’s stock grew significantly faster than SYRE’s over the last 12 months.

TRVI's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as SYRE (96). This means that TRVI’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is in the same range as TRVI (63). This means that SYRE’s stock grew similarly to TRVI’s over the last 12 months.

SYRE's P/E Growth Rating (71) in the Pharmaceuticals Major industry is in the same range as TRVI (100). This means that SYRE’s stock grew similarly to TRVI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYRETRVI
RSI
ODDS (%)
Bullish Trend 5 days ago
89%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
88%
N/A
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
N/A
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
87%
N/A
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 4 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
COMPARISON
Comparison
Oct 12, 2026
Stock price -- (SYRE: $85.69 vs. TRVI: $13.19)
Brand notoriety: SYRE and TRVI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 93% vs. TRVI: 122%
Market capitalization -- SYRE: $7.56B vs. TRVI: $2.05B
SYRE [@Biotechnology] is valued at $7.56B. TRVI’s [@Biotechnology] market capitalization is $2.05B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green while TRVI’s FA Score has 1 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • TRVI’s FA Score: 1 green, 4 red.
According to our system of comparison, TRVI is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 5 TA indicator(s) are bullish while TRVI’s TA Score has 3 bullish TA indicator(s).

  • SYRE’s TA Score: 5 bullish, 4 bearish.
  • TRVI’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, both SYRE and TRVI are a good buy in the short-term.

Price Growth

SYRE (@Biotechnology) experienced а -8.05% price change this week, while TRVI (@Biotechnology) price change was -5.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.51%. For the same industry, the average monthly price growth was -13.43%, and the average quarterly price growth was -4.26%.

Reported Earning Dates

SYRE is expected to report earnings on Nov 05, 2026.

TRVI is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-2.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
SYRE
Daily Signal:
Gain/Loss:
TRVI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
TVAL42.850.26
+0.61%
T. Rowe Price Value ETF (TVAL)
REGS11.800.07
+0.55%
Columbia Large Cap Growth ETF (REGS)
IMTB41.420.01
+0.02%
iShares Core 5-10 Year USD Bond ETF (IMTB)
CVNY17.54-0.03
-0.15%
YieldMax CVNA Option Income Strategy ETF
TVE23.08-0.14
-0.60%
Tennessee Valley Authority Power Bonds 1999 Series A due May 1 2029

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with ORKA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then ORKA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+7.25%
ORKA - SYRE
53%
Loosely correlated
+6.25%
IMVT - SYRE
45%
Loosely correlated
+0.69%
BEAM - SYRE
45%
Loosely correlated
+4.47%
PMN - SYRE
44%
Loosely correlated
+4.00%
RCKT - SYRE
44%
Loosely correlated
-2.66%
More

TRVI and

Correlation & Price change

A.I.dvisor indicates that over the last year, TRVI has been loosely correlated with PCVX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TRVI jumps, then PCVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TRVI
1D Price
Change %
TRVI100%
+2.85%
PCVX - TRVI
41%
Loosely correlated
+9.79%
RAPP - TRVI
40%
Loosely correlated
+2.68%
SYRE - TRVI
40%
Loosely correlated
+7.25%
ORKA - TRVI
40%
Loosely correlated
+6.25%
KURA - TRVI
40%
Loosely correlated
+0.76%
More